1980 Results
Sort By:
Published on June 25, 2014
Personalized medicine is gaining momentum, but it needs yet more impetus to break into the healthcare mainstream, argues a new report. Released on June 25 by the Personalized Medicine Coalition (PMC), the report examines opportunities for the continued development and adoption of personalized medicine as the cost of genetic sequencing…
Published on June 12, 2014
Technological advances such as high-throughput sequencing are transforming medicine from symptom-based diagnosis and treatment to personalized medicine as scientists employ novel rapid genomic methodologies to gain a broader comprehension of disease and disease progression. As next-generation sequencing becomes more rapid, researchers are turning toward large-scale pan-omics, the collective use of…
Published on June 10, 2014
This report represents qualitative and quantitative metrics of the next-generation sequencing (NGS) landscape and frames it into the context of various biomarker classes. Highlights of this report: The NGS field is expanding and its quantitative penetrance into clinical testing is growing. We present in this report some data illustrating the…
Published on May 28, 2014
The history of science is replete with instances of multiple discovery—the more or less simultaneous announcement of essentially the same breakthrough by independent researchers. Still, it may still seem uncanny that two separate research groups not only produced a draft map of the human proteome, they also published their results…
Published on May 20, 2014
With a little help from Sloan Kettering Institute chair Marie-Josée Kravis and her husband, philanthropist Henry R. Kravis, the Memorial Sloan Kettering Cancer Center (MSK) is launching a new program that it says will reshape clinical trials and speed up translation of molecular discoveries into routine clinical practice. Dubbed the…
Published on May 16, 2014
The use of targeted agents against key signaling kinases is transforming cancer treatment. Drugs such as Herceptin and Zelboraf have increased progression-free survival in breast cancer and melanoma respectively and are far from the only examples. However, the complexity of signaling pathway networks allows tumor cells to adapt under monotherapy…
Published on May 16, 2014
N-of-One inked an agreement with Belgian personalized medicine firm OncoDNA under which it will provide clinical interpretation for all of OncoDNA's next-generation sequencing (NGS) and other molecular tests for patients throughout Europe, the Middle East, and other parts of the world. OncoDNA provides tumor profiling services designed to help medical…
Published on May 15, 2014
Next-generation sequencing (NGS) has been making tremendous strides in the research market and with Illumina’s recent launch of the HiSeq X Ten, we’ve essentially reached the $1,000 genome (notwithstanding quibbles over what exactly should be accounted for in the $1,000). With these advancements, the pull to adapt NGS for the…
Published on May 15, 2014
While the first traffic light flashed 18 years before the first car was built, the rules of the road have long lagged behind technology where genetic testing is concerned, especially in distinguishing functional gene variants from those that cause disease. That is starting to change as groups of researchers and…
Published on May 15, 2014
In 2009 Mark Boguski and colleagues published a paper entitled “Customized care 2020: how medical sequencing and network biology will enable personalized medicine.” In the paper the authors described a model incorporating these pathways, annotation of disease networks and drug targets, and simulation of therapeutic interventions with virtual drugs or…
Published on May 15, 2014
Cancer Genetics said today it acquired Indian-based BioServe Biotechnologies for about $1.9 million, primarily in stock and other deferred payments, in a deal designed to help the buyer scale up its genetic analysis, bioinformatics, and manufacturing operations while capitalizing on clinical diagnostics and trial growth in India and the Asian…
Published on May 6, 2014
Like travelers who roam curious lands, oncologists who delve into tumor genetics may find themselves in need of local guides, experts who will put them on the right path. As far as oncologists are concerned, the right path is the one that leads to an effective therapy, but in difficult-to-treat…
Published on April 17, 2014
The name of one thing or another, in isolation, may seem arbitrary, as poets and artists have suggested from time to time. Scientists, however, have a different perspective. They cannot accept, as a painter once declared, that the “precision of naming takes away from the uniqueness of seeing.” For scientists,…
Published on April 16, 2014
It is not a question of if molecular profiling—the gamut of omics technologies—will enter the clinic, or even when. Clinical omics is happening now. And so, questions about clinical omics are taking a more practical turn, particularly for those who have a professional interest in overseeing, or at least accommodating,…
Published on April 11, 2014
Development of better, cheaper, and more clinically relevant genomic analysis continues apace, but what about the proteome? If anything, the proteome—the full set of expressed proteins—would tell us more about wellness and ill health than the genome. True, genes constitute the foundation of life’s chemical hierarchy, but proteins (to mix…